R/R MM: Insights Into Optimal Dosing for Bispecifics

Panelist discusses how bispecifics have had a major impact in relapsed/refractory multiple myeloma (R/R MM) because they provide a different way of attacking myeloma, allow oncologists an opportunity to care for patients who cannot have CAR T therapy, and allow oncologist to treat patients who have had an aggressive relapse. The panelist further discusses the importance of bispecifics dosing specifically to maintain a response with the drug but also to prevent the risk of patient infection.